ISSN: 2278-0238

Revue internationale de recherche et développement en pharmacie et sciences de la vie

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

REVIEW ON PHARMACOLOGICAL ACTIVITIES OF LIGUSTRUM OVALIFOLIUM

Harsha Matoli, Ashish Mangal, Pranav Vashistha, Megha Jain, love S. Chokotia

The identification of privet in the middle southern United States can be difficult. Because most introduced species of privet can be invasive, and recent mapping projects seek location and species population data, proper identification is important. Ligustrum is currently marketed as a treatment for strengthening the immune system, R 3\05\ 9and on this basis is often recommended for use by people undergoing treatment for cancer or HIV. There is no meaningful scientific evidence that ligustrum provides any benefit for these, or any other, conditions. Very weak evidence from test-tube and animal studies hints that ligustrum might have anti-parasitic, 1 anti-viral, 2l iver-protective , 3immunomodulatory (this means “altering” immune function, rather than, as commonly misunderstood, “strengthening” it), 4,5 and cancer-preventive 6 effects. However, this evidence is too preliminary to rely upon at all. Ligustrum ovalifolium are used the activities of hypotensive activity, hypoglycemic activity, anti inflammatory activity and antioxidant activity.